ICCC Valuation

ImmuCell Corp

Add to Watchlist

Advanced Chart

6.250

+0.165(2.712%)1D

Overview
Forecast
Valuation
Earnings

ICCC Relative Valuation

ICCC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ICCC is overvalued; if below, it's undervalued.

Historical Valuation

ImmuCell Corp (ICCC) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.31 is considered Undervalued compared with the five-year average of -59.55. The fair price of ImmuCell Corp (ICCC) is between 30.20 to 32.85 according to relative valuation methord. Compared to the current price of 6.08 USD , ImmuCell Corp is Undervalued By 79.85%.

Relative Value

Fair Zone

30.20-32.85

Current Price：6.08

79.85%

Undervalued

-55.32

Trailing

Forward

0.00

EV/EBITDA

ImmuCell Corp. (ICCC) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-82.32

EV/EBIT

ImmuCell Corp. (ICCC) has a current EV/EBIT of -82.32. The 5-year average EV/EBIT is -75.73. The thresholds are as follows: Strongly Undervalued below -107.84, Undervalued between -107.84 and -91.79, Fairly Valued between -59.67 and -91.79, Overvalued between -59.67 and -43.62, and Strongly Overvalued above -43.62. The current Forward EV/EBIT of -82.32 falls within the Historic Trend Line -Fairly Valued range.

3.31

ImmuCell Corp. (ICCC) has a current PS of 3.31. The 5-year average PS is 3.12. The thresholds are as follows: Strongly Undervalued below 1.32, Undervalued between 1.32 and 2.22, Fairly Valued between 4.02 and 2.22, Overvalued between 4.02 and 4.92, and Strongly Overvalued above 4.92. The current Forward PS of 3.31 falls within the Historic Trend Line -Fairly Valued range.

26.05

P/OCF

ImmuCell Corp. (ICCC) has a current P/OCF of 26.05. The 5-year average P/OCF is 16.57. The thresholds are as follows: Strongly Undervalued below -103.03, Undervalued between -103.03 and -43.23, Fairly Valued between 76.37 and -43.23, Overvalued between 76.37 and 136.17, and Strongly Overvalued above 136.17. The current Forward P/OCF of 26.05 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

ImmuCell Corp. (ICCC) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

ImmuCell Corp (ICCC) has a current Price-to-Book (P/B) ratio of 1.85. Compared to its 3-year average P/B ratio of 1.57 , the current P/B ratio is approximately 17.39% higher. Relative to its 5-year average P/B ratio of 1.78, the current P/B ratio is about 3.89% higher. ImmuCell Corp (ICCC) has a Forward Free Cash Flow (FCF) yield of approximately 3.20%. Compared to its 3-year average FCF yield of -9.50%, the current FCF yield is approximately -133.71% lower. Relative to its 5-year average FCF yield of -7.21% , the current FCF yield is about -144.38% lower.

1.84

P/B

Median3y

1.57

Median5y

1.78

3.20

FCF Yield

Median3y

-9.50

Median5y

-7.21

Competitors Valuation Multiple

The average P/S ratio for ICCC's competitors is 66.69, providing a benchmark for relative valuation. ImmuCell Corp Corp (ICCC) exhibits a P/S ratio of 3.31, which is -95.04% above the industry average. Given its robust revenue growth of 17.76%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Incannex Healthcare Inc

Maia Biotechnology Inc

Loss

50.81M

DTIL.O

Precision BioSciences Inc

Performance Decomposition

Market capitalization of ICCC increased by 67.11% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 10.94 to 30.33.

The secondary factor is the Revenue Growth, contributed 17.76%to the performance.

Overall, the performance of ICCC in the past 1 year is driven by P/E Change. Which is more unsustainable.

17.76%

5.47M → 6.44M

Revenue Growth

-127.83%

-27.99 → 7.79

Margin Expansion

177.18%

10.94 → 30.33

P/E Change

67.11%